Glyburide appears worthwhile to try the treatment failure does not hurt

Glyburide to achieve control gestational diabetes, but in about 20% of patients, not a trial of glyburide appear to affect long-term, Meredith Rochon, MD, department of obstetrics, gynecology, science and Mount Sinai School of Medicine, ew York, and colleagues reported.

Glyburide therapy has proved effective and safe for gestational diabetes.

Researchers examined the records of all patients with class A2 gestational diabetes treated with glyburide in clinical diabetes over a period of 2 years to ensure no adverse effects when treatment has failed.

The study found no reason to avoid the use of insulin instead of glyburide as first line treatment, the researchers wrote in a poster presented at the annual meeting of the Society for Maternal-Fetal Medicine.

Among the 83 patients identified, 18 (22%) were patients who had undergone a trial of glyburide, but not to achieve the objective of fasting and postprandial blood glucose of 60-90 mg / dl and 120 mg / dL, respectively even when treated with a dose of 20 mg per day. Therefore, patients who have gone to insulin.

Despite its initial failure to control blood glucose, pregnancy outcome in patients who have no treatment - including birth weight, mode of delivery and the incidence of macrosomia - are not different from those glyburide success.

The only difference in outcomes in patients Successfully Treated with Glyburide. Patients were younger children who require admission to the neonatal unit for intensive care (NICU) that women who switched to insulin (35% vs. 11%) The most common reason for admission is the 'hypoglycaemia (10 of 23 entries).

In an interview, Dr. Rochon said the finding was a surprise and something of a mystery, like glyburide does not cross the placenta, and previous studies have not taken note of this potential association.

Hypoglycemia was not considered by investigators to be a serious adverse effect was transient, because in all cases.